GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Supernus Pharmaceuticals Inc (LTS:0LB2) » Definitions » Cyclically Adjusted Book per Share

Supernus Pharmaceuticals (LTS:0LB2) Cyclically Adjusted Book per Share : $10.34 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Supernus Pharmaceuticals Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Supernus Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2024 was $16.905. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $10.34 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Supernus Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was 19.70% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 43.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Supernus Pharmaceuticals was 63.60% per year. The lowest was 43.20% per year. And the median was 53.40% per year.

As of today (2024-05-17), Supernus Pharmaceuticals's current stock price is $28.70. Supernus Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $10.34. Supernus Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 2.78.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Supernus Pharmaceuticals was 24.68. The lowest was 2.42. And the median was 5.03.


Supernus Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

The historical data trend for Supernus Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Supernus Pharmaceuticals Cyclically Adjusted Book per Share Chart

Supernus Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.80 3.70 7.45 8.19 10.28

Supernus Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.84 9.17 10.26 10.28 10.34

Competitive Comparison of Supernus Pharmaceuticals's Cyclically Adjusted Book per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Supernus Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Supernus Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Supernus Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Supernus Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Supernus Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Supernus Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=16.905/131.7762*131.7762
=16.905

Current CPI (Mar. 2024) = 131.7762.

Supernus Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.792 100.560 1.038
201409 1.540 100.428 2.021
201412 0.947 99.070 1.260
201503 1.991 99.621 2.634
201506 2.113 100.684 2.766
201509 2.248 100.392 2.951
201512 1.796 99.792 2.372
201603 2.593 100.470 3.401
201606 2.848 101.688 3.691
201609 3.500 101.861 4.528
201612 3.837 101.863 4.964
201703 4.103 102.862 5.256
201706 4.522 103.349 5.766
201709 4.909 104.136 6.212
201712 5.213 104.011 6.605
201803 6.815 105.290 8.529
201806 7.484 106.317 9.276
201809 8.074 106.507 9.990
201812 8.659 105.998 10.765
201903 9.165 107.251 11.261
201906 9.970 108.070 12.157
201909 10.622 108.329 12.921
201912 11.334 108.420 13.776
202003 11.675 108.902 14.127
202006 12.655 108.767 15.332
202009 13.459 109.815 16.151
202012 14.089 109.897 16.894
202103 14.236 111.754 16.787
202106 14.782 114.631 16.993
202109 15.240 115.734 17.352
202112 15.319 117.630 17.161
202203 15.518 121.301 16.858
202206 15.730 125.017 16.580
202209 15.777 125.227 16.602
202212 16.334 125.222 17.189
202303 16.746 127.348 17.328
202306 16.850 128.729 17.249
202309 16.697 129.860 16.943
202312 16.840 129.419 17.147
202403 16.905 131.776 16.905

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Supernus Pharmaceuticals  (LTS:0LB2) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Supernus Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=28.70/10.34
=2.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Supernus Pharmaceuticals was 24.68. The lowest was 2.42. And the median was 5.03.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Supernus Pharmaceuticals Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Supernus Pharmaceuticals's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Supernus Pharmaceuticals (LTS:0LB2) Business Description

Traded in Other Exchanges
Address
9715 Key West Avenue, Rockville, MD, USA, 20850
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Supernus Pharmaceuticals (LTS:0LB2) Headlines

No Headlines